EXEL vs. GSK: Exelixis vs. GSK Stock Comparison

Company Profile

Exelixis (EXEL) and GSK (GSK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but EXEL is classified in Biotechnology while GSK is classified in Pharmaceuticals.

Exelixis (EXEL) trades as ordinary local shares, while GSK (GSK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Exelixis (EXEL) at 44.32% and GSK (GSK) at 28.27% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Exelixis (EXEL) at 35.45% keeps the most of each sales dollar — above its industry’s net margin range — and GSK (GSK) at 12.97% also retains a top-quartile share.

Both Exelixis (EXEL) at 40.75% and GSK (GSK) at 32.14% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Exelixis (EXEL) at 6.98% and GSK (GSK) at 4.11% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

GSK (GSK) at 123.15% sits in the top EPS growth quartile, while Exelixis (EXEL) at 57.95% is closer to the peer norm — faster per-share earnings growth for GSK.

Growth Metrics

Financial Strength

Exelixis (EXEL) at 3.21 keeps current ratio within its industry’s typical mid-range, while GSK (GSK) at 0.86 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GSK.

Exelixis (EXEL) at 0.09 carries an industry-typical debt-to-equity mix, while GSK (GSK) at 1.30 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Exelixis (EXEL) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a yield of 1.57%, ranking against industry peers normally.

Exelixis (EXEL) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a payout of 63.33%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both Exelixis (EXEL) at 20.83 and GSK (GSK) at 17.54 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

GSK (GSK) at 3.01 sits in the cheaper P/S ratio quartile while Exelixis (EXEL) at 6.80 prices around its industry’s middle — GSK costs less per dollar of sales, though read it alongside growth and margins.

GSK (GSK) at 4.02 is valued about in line with its industry on P/B ratio, while Exelixis (EXEL) at 9.28 carries an above-peer premium to book — EXEL is pricier on assets.

Valuation Metrics